Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows: Session: Advances in Oncology PanelPresenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ETLocation: NYY Room at the Hard Rock Hotel NYC Mr. Klemp will discuss Mole
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposom
Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer
- Video webcast now available here HOUSTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it participated in the Virtual Investor “Why Now” on-demand conference. During the presentation, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, highlighted the Company's clinical progress and long-term opportunity, discussing encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annam
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This is the newest page. Registered accounts read further back.